Pituitary Tumor, Sellar and Suprasellar Masses
Conditions
Brief summary
1. Access the optimal cut point value of copeptin which predicts development of central diabetes insipidus postoperatively with highest accuracy. 2. Access the optimal cut point value of copeptin which predicts the lack of central diabetes insipidus postoperatively with highest accuracy 3. Access the relative change in copeptin values between baseline and post-surgery as a predictor for diabetes insipidus development.
Detailed description
Patient serum levels of copeptin would be measured after phlebotomy of 3 ml of blood in EDTA tube twice a) within 1-4 hours of extubation and b) within 4-24 hours of extubation (the morning following surgery).
Interventions
None listed
Sponsors
Mayo Clinic
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
No
Inclusion criteria
\* Patients with sellar and suprasellar masses who undergo neurosurgical procedure at Mayo Clinic Rochester.
Exclusion criteria
\* Patients with preexisting CDI.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Predict central diabetes insipidus development | 2 years | Using the measured lab value, we will access the optimal cut point value of copeptin which predicts development of central diabetes insipidus postoperatively with highest accuracy. |
| Predict lack of central diabetes insipidus development | 2 years | Using the measured lab value, we will access the optimal cut point value of copeptin which predicts the lack of central diabetes insipidus postoperatively with highest accuracy |
| Assess relative change | 2 years | Using the measured lab value, we will access the relative change in copeptin values between baseline and post-surgery as a predictor for diabetes insipidus development. |
Countries
United States
Outcome results
None listed